Clinical trial · Observational
Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms
Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms.
NCT05553067CI-TRIAL-00061059completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Detection of the potential oncogenic role of Engrailed-2 in epithelial ovarian neoplasms, in order to detect biological markers that could be targeted and blocked by new medications.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunohistochemical staining of normal and neoplastic ovarian tissues by anti human Engrailed-2 antibody. | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- compare levels of Engrailed-2 expression in different ovarian specimens.
- timeFrame
- December, 2021
- description
- compare levels of immunohistochemical expression of Engrailed-2 in normal and neoplastic ovarian tissues. and correlate Engrailed-2 expression in neoplastic ovarian tissues to patients' ages, tumor phenotype and state of nodal metastasis.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * All types of epithelial ovarian neoplasms (benign, borderline and malignant). Exclusion Criteria: * Non-epithelial and/ or secondary ovarian tumors. * Cases with poor clinical data. * Cases who had history of pre-operative chemotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.